H.A. Intensifier is a multi-beneficial corrective serum proven to amplify skin’s hyaluronic acid levels. This unique formulation contains a high concentration of pure hyaluronic acid, proxylane™, and botanical extracts of licorice root and purple rice to support skin’s hyaluronic acid levels and deliver surface hydration, helping improve the visible appearance of firmness, smoothness, and facial plumpness. This hyaluronic acid serum may be used as part of a home skincare regimen after dermal fillers; always consult with your physician for individual at-home advice.
Hyaluronic acid naturally occurs in the skin and plays an important role in maintaining moisture. This essential molecule, however, has a short lifecycle in the skin, with 30%-50% degrading every 24 hours. With age, the skin’s ability to produce hyaluronic acid decreases. Production starts to decline in the 20s and this decline accelerates in the 40s. Decreased production rapid degradation of hyaluronic acid contribute to signs of aging, including decreased firmness, less facial plumpness, and rough texture.
While hyaluronic acid is a powerful hydrator, the size of the hyaluronic acid molecules are too large for optimal skin absorption. H.A. Intensifier uniquely combines surface-hydrating hyaluronic acid with 10% proxylane™ and an optimal concentration of licorice and purple rice extracts to support skin’s hyaluronic acid levels.
In a 12-week clinical study, H.A. Intensifier significantly improved the appearance of key aging indicators:
- 23% improvement in plumpness
- 9% decrease in sagginess
- 11% improvement in firmness
- 13% improvement in elasticity
- 18% improvement in texture
Protocol: A 12-week, single-center, clinical study was conducted on 59 females, ages 42-60, with mild to moderate facial sagging and loss of firmness, rough skin texture, nasolabial fold wrinkles, marionette lines, and presence of fine lines/wrinkles in the crow’s feet area. H.A. Intensifier was used twice daily in conjunction with SkinCeuticals Gentle Cleanser and a sunscreen. Efficacy and tolerability evaluations were conducted at baseline and at weeks 4, 8, and 12.